active vitamin D

DRUG4 trials

Conditions

Disorders of Parathyroid GlandHyperparathyroidismHypoparathyroidism Post-surgicalMaintenance HemodialysisPostoperative HypoparathyroidismPostsurgical HypoparathyroidismSecondary HyperparathyroidismX-Linked Hypophosphatemia

Phase 3

Efficacy and Safety of Burosumab Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With XLH

CompletedNCT02915705

Kyowa Kirin, Inc.X-Linked Hypophosphatemia

Start: 2016-09-08End: 2019-07-15Updated: 2024-08-29

Unknown Phase

Efficacy and Safety of Ultrasonic Ablation to Treat Secondary Hyperparathyroidism in Chronic Kidney Disease Patients

CompletedNCT01640184

Dongliang Zhang, MDDisorders of Parathyroid Gland, Hyperparathyroidism

Start: 2012-08-31End: 2014-11-30Updated: 2016-10-17

The Efficacy and Safety of Microwave Ablation for Mild-to-moderate Secondary Hyperparathyroidism Patients Undergoing Hemodialysis

NCT02332135

Wenhu LiuMaintenance Hemodialysis, Secondary Hyperparathyroidism

Start: 2015-01-31End: 2018-03-31Target: 30Updated: 2016-05-24

PRESS -PAR: Early Detection and PREvention of Symptomatic postSurgical hypoPARathyroidism After Thyroid Surgery"

RecruitingNCT07491601

Nicolas SchlegelHypoparathyroidism Post-surgical, Postoperative Hypoparathyroidism, Postsurgical Hypoparathyroidism

Start: 2025-01-08End: 2029-12-31Target: 336Updated: 2026-03-24

Journal of Bone and Mineral Research2024-08-1615 citations

Self-Administration of Burosumab in Children and Adults with X-Linked Hypophosphataemia in Two Open-Label, Single-Arm Clinical Studies.

2023-01-316 citations

Sustained Efficacy and Safety of Burosumab, a Monoclonal Antibody to FGF23, in Children With X-Linked Hypophosphatemia

The Journal of Clinical Endocrinology & Metabolism2021-10-1280 citations

Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked Hypophosphatemia.

2021-01-2335 citations

SUN-356 Burosumab Resulted in Greater Clinical Improvements Compared with Higher-dose Conventional Therapy in Children with X-linked Hypophosphatemia (XLH)

Journal of the Endocrine Society2020-04-01

Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial.

2019-05-16235 citations

OR13-2 Burosumab Resulted in Greater Improvement in Rickets Than Conventional Therapy in Children with X-Linked Hypophosphatemia (XLH)

Journal of the Endocrine Society2019-04-01

active vitamin D

Sponsors

Conditions

Phase 3

Unknown Phase

Related Papers